Epigallocatechin gallate attenuates ET-1-induced contraction in carotid artery from type 2 diabetic OLETF rat at chronic stage of disease  by Matsumoto, Takayuki et al.
Life Sciences 118 (2014) 200–205
Contents lists available at ScienceDirect
Life Sciences
j ourna l homepage: www.e lsev ie r .com/ locate / l i fesc ieEpigallocatechin gallate attenuates ET-1-induced contraction in carotid
artery from type 2 diabetic OLETF rat at chronic stage of diseaseTakayuki Matsumoto, Shun Watanabe, Ryusuke Kawamura, Kumiko Taguchi, Tsuneo Kobayashi ⁎
Department of Physiology and Morphology, Institute of Medicinal Chemistry, Hoshi University, Shinagawa-ku, Tokyo 142-8501, Japan⁎ Corresponding author. Tel./fax: +81 3 5498 5849.
E-mail address: tkoba@hoshi.ac.jp (T. Kobayashi).
http://dx.doi.org/10.1016/j.lfs.2013.11.016
0024-3205 © 2013 The Authors. Published by Elsevier Inca b s t r a c ta r t i c l e i n f oArticle history:
Received 24 September 2013
Accepted 18 November 2013
Available online 1 December 2013
Keywords:
Carotid artery
EGCG
ET-1
Type 2 diabetes
Vasoconstriction
Aims: There is a growing body of evidence suggesting that epigallocatechin gallate (EGCG), a major catechin
isolated from green tea, has several beneﬁcial effects, such as anti-oxidant and anti-inﬂammatory activities.
However, whether treatment with EGCG can suppress the endothelin-1 (ET-1)-induced contraction in carotid
arteries from type 2 diabetic rats is unknown, especially at the chronic stage of the disease. We hypothesized
that long-term treatment with EGCG would attenuate ET-1-induced contractions in type 2 diabetic arteries.
Main methods: Otsuka Long–Evans Tokushima fatty (OLETF) rats (43 weeks old) were treated with EGCG
(200 mg/kg/day for 2 months, p.o.), and the responsiveness to ET-1, phenylephrine (PE), acetylcholine
(ACh) and sodium nitroprusside (SNP) was measured in common carotid artery (CA) from EGCG-treated and -
untreated OLETF rats and control Long–Evans Tokushima Otsuka (LETO) rats.
Key ﬁndings: In OLETF rats, EGCG attenuated responsiveness to ET-1 in CA compared to untreated groups. How-
ever, EGCG did not alter PE-induced contractions in CA from OLETF rats. In endothelium-denuded arteries, EGCG
did not affect ET-1-induced contractions in either the OLETF or LETO group. Acetylcholine-induced relaxation
was increased by EGCG treatment in CA from the OLETF group. The expressions of ET receptors, endothelial nitric
oxide synthase, superoxide dismutases, and gp91phox [an NAD(P)H oxidase component] in CA were not altered
by EGCG treatment in either group.
Signiﬁcance: Our data suggest that, within the timescale investigated here, EGCG attenuates ET-1-induced
contractions in CA from type 2 diabetic rats, and one of the mechanisms may involve normalizing endothelial
function.© 2013 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/3.0/).Introduction
Facedwith a global epidemic of type 2 diabetesmellitus (T2DM), it is
critical that we improve our understanding of the pathogenesis of T2DM
and related vascular complications (Forbes and Cooper, 2013). These
ﬁndings may ultimately lead to novel treatment options for disease
prevention or delaying the progression of complications (Forbes and
Cooper, 2013). The mechanisms regulating the functions of endothelial
cells (ECs) and vascular smooth muscle cells (VSMCs) are important
therapeutic targets for diabetic vascular complications (Forbes and
Cooper, 2013; Porter and Riches, 2013). General therapies for diabetes
and its associated vascular complications that are both effective and
safe are insufﬁcient to match rising demand. Therefore, developing
alternative approaches for the treatment as well as prevention of
diseases is imperative. One promising alternative therapeutic ﬁeld is
functional foods (Munir et al., 2013; van Dam et al., 2013). A number
of large, well-performed epidemiologic studies have demonstrated that
the consumption of functional foods containing bioactive polyphenols. This is an open access article underincluding green tea is associated with the normalization of metabolic
and/or vascular dysfunction (Munir et al., 2013; van Dam et al., 2013).
Recently, there is a growing body of evidence suggesting that green
tea polyphenols, especially the most abundant green tea catechin,
epigallocatechin gallate (EGCG), have beneﬁcial effects on cardiovascu-
lar and metabolic health (Wolfram, 2007; Babu and Liu, 2008). For
example, EGCG has anti-inﬂammatory, anti-angiogenic, and anti-
proliferative effects on both ECs and VSMCs (Peng et al., 2010; Wang
et al., 2010; Yang et al., 2011, 2013). Moreover, some studies reported
that the preventive effects of EGCG on the development of vascular
inﬂammation were seen in the db/db mouse aorta (Babu et al., 2012)
and on aortic reactivity in streptozotocin-induced diabetic rats (Roghani
and Baluchnejadmojarad, 2009). Potenza et al. (2007) found that, in
SHR rats, 3 weeks of EGCG administration (starting at 9 weeks old)
reduces insulin resistance, inhibits hypertension, protects against cardiac
ischemia/reperfusion injury, raises plasma adiponectin levels, and
improves endothelial dysfunction. Anti-diabetic or lipid-lowering effects
of EGCG or green tea have been demonstrated in rodent models of
T2DM as well as obesity (Sabu et al., 2002; Munir et al., 2013).
Endothelin-1 (ET-1) is a potent vasoconstrictor, proinﬂammatory,
and proliferative peptide derived from ECs that plays an importantthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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2012; Pernow et al., 2012). The expression and functional effects of ET-1
and signaling of its receptors (i.e., ETA and ETB receptors) are markedly
altered during the development of cardiovascular diseases, including
T2DM (Matsumoto et al., 2009a; Ergul, 2011; Pernow et al., 2012). Al-
though EGCG couldmodulate the ET-1 system in in vitro cellularmodels
(Reiter et al., 2010; Wang et al., 2010), the effects of long-term treat-
ment with EGCG on ET-1-induced contraction in T2DM arteries remain
unclear.
Otsuka Long–Evans Tokushima fatty (OLETF) rats manifest stable
clinical and pathological features that resemble human T2DM (Kawano
et al., 1992). Based on thismodel, there have been several reports of vas-
cular dysfunctions in various arteries (Kagota et al., 2000; Matsumoto
et al., 2009b). Various studies on animal models of cardiovascular dis-
eases have investigated the preventive effects of catechin or green tea
when treatment is started before the onset of complications or at a
young age (Ihm et al., 2009, 2012). However, treatment of T2DM pa-
tients does not begin until after they have been diagnosed, at which
time, in many instances, complications are already present. Therefore,
to clarify whether EGCG has therapeutic effects, evidence from EGCG
treatment an already established T2DMmodel would be necessary.
In the present study, we investigated the effects of long-term EGCG
treatment on the ET-1-induced contraction of carotid arteries isolated
from OLETF rats at the established chronic stage of T2DM, and clariﬁed
some of the underlying molecular mechanisms.
Materials and methods
Materials
Phenylephrine (PE), sodium nitroprusside (SNP), and monoclo-
nal β-actin antibody were purchased from Sigma Chemical Co. (St.
Louis, MO, USA), while acetylcholine chloride (ACh) was purchased
from Daiichi-Sankyo Pharmaceuticals (Tokyo, Japan). ET-1 was
from Peptide Institute (Osaka, Japan). Horseradish peroxidase
(HRP)-linked secondary antibodies were purchased from Promega
(Madison, WI, USA). Extracellular superoxide dismutase (EC-SOD)
antibody was from Upstate (Lake Placid, NY, USA). Antibodies for ETA
and ETB were from Abcam (Cambridge, UK), while eNOS, Mn-SOD,
and gp91phox antibodies were from BD Biosciences (San Jose, CA,
USA). Cu/Zn-SOD was from Stressgen (Victoria, BC, Canada). EGCG
was purchased from ACCESSONE CO. Ltd. (Chiba, Japan).
Animals and experimental design
Four-week-oldmale LETO rats (a genetic control of OLETF) and OLETF
rats were obtained from Hoshino Laboratory Animals, Inc. (Ibaraki,
Japan). Food andwaterwere given ad libitum in a controlled environment
(room temperature: 21–22 °C, humidity: 50 ± 5%) until the rats were
43 weeks old. This study was approved by the Hoshi University Animal
Care and Use Committee, and all studies were conducted in accordance
with the “Guide for the Care and Use of Laboratory Animals”, published by
the US National Institutes of Health, and with the “Guide for the Care and
Use of Laboratory Animals” adopted by the Committee on the Care and
Use of Laboratory Animals of Hoshi University (accredited by theMinistry
of Education, Culture, Sports, Science, and Technology, Japan).
For the long-term treatment study, some LETO and OLETF rats were
given EGCG (200 mg/kg/day, p.o.) for 2 months starting at 43 weeks
old. Thus, we studied four groups: EGCG-treated or -untreated LETO
and OLETF groups. EGCG was dissolved in ultrapure water before
treatment every day and administered by gavage.
Measurement of blood parameters and blood pressure
Plasma parameters and systolic blood pressure were measured as
described previously (Matsumoto et al., 2009a,b, in press). Brieﬂy,plasma insulinwasmeasuredwith an enzyme immunoassay (Shibayagi
Co., Ltd., Gunma, Japan). Plasma cholesterol, triglyceride, high-density
lipoprotein (HDL) cholesterol, and nonesteriﬁed fatty acid (NEFA) levels
were detected with a commercially available enzyme kit (Wako, Osaka,
Japan). Plasma glucose was measured using a commercially available
glucose meter (OneTouch Ultra, LifeScan, a Johnson & Johnson Compa-
ny,Milpitas, CA, USA). Systolic blood pressurewasmeasured employing
the tail-cuff method using a blood pressure analyzer (BP-98A; Softron,
Tokyo, Japan) after the rat had been in a constant-temperature box at
37 °C for at least 5 min.
Functional studies
In all experiments, non-fasted rats were anesthetized with isoﬂurane
via a nose cone for surgical procedures (initiallywith 5.0% and thenmain-
tained at 2.5%) and euthanized by thoracotomy and exsanguination via
cardiac puncture. The arterial isometric force was recorded as previously
described (Matsumoto et al., 2009a,b, in press). After euthanasia, the
common carotid artery was isolated and placed in an ice-cold, oxygen-
ated, modiﬁed Krebs–Henseleit Solution (KHS). This solution consisted
of (inmM) 118.0 NaCl, 4.7 KCl, 25.0 NaHCO3, 1.8 CaCl2, 1.2 NaH2PO4, 1.2
MgSO4, and 11.0 glucose. The artery was carefully cleaned of all fat and
connective tissue, and ring segments of 2 mm in length were
suspended by a pair of stainless-steel pins in a well-oxygenated (95%
O2–5% CO2) bath containing 10 mL of KHS at 37 °C. The rings were
stretched until an optimal resting tension of 9.8 mN [the resting tension
predetermined to elicit maximal active tension responses to potassium
chloride (KCl) in arterial rings in preliminary experiments] was loaded,
and then they were allowed to equilibrate for at least 45 min. Force
generation was monitored with an isometric transducer (model TB-
611 T; Nihon Kohden, Tokyo, Japan). Arterial integrity was checked
by contracting the rings with KCl (80 mM) and subsequently with PE
(10−6 M), followed by relaxation with ACh (10−6 or 10−5 M).
After washing and re-stabilization, ET-1 (10−10–10−7 M) or PE
(10−10–10−4 M) was applied cumulatively to the bath until a
maximal response was achieved. When required, removal of the en-
dothelium was achieved by infusing a 3-[(3-cholamidopropyl)
dimethylammonio]-1-propanesulfonate solution (CHAPS, 0.1%, for
60 s) for carotid arterial segments, which was subsequently ﬂushed
out with KHS; the inability of ACh (10−5 M) to relax these segments
conﬁrmed the success of this procedure, as reported previously
(Matsumoto et al., 2009a,b, in press).
For the relaxation studies, when the PE (10−6 M)-induced contrac-
tion reached a plateau, ACh (10−9–10−5 M) and SNP (10−10–10−5 M)
were added in a cumulative manner.
Western blotting
Protein expressions were measured as described previously
(Matsumoto et al., 2009a,b, in press). Brieﬂy, carotid arterial tissues
were homogenized in ice-cold radioimmunoprecipitation assay (RIPA)
buffer [25 mM Tris–HCl (pH 7.6), 150 mM NaCl, 1% Nonidet P-40, 1%
sodium deoxycholate, and 0.1% SDS] (ThermoScientiﬁc, Rockford, IL,
USA) containing protease- and phosphatase-inhibitor cocktails (Roche
Diagnostics, Indianapolis, IN, USA). The lysate was cleared by centrifu-
gation at 16,000 g for 10 min at 4 °C. The supernatant was collected,
and the proteins were solubilized in Laemmli's buffer containing
mercaptoethanol. Equal amounts of protein were resolved by electro-
phoresis on SDS-PAGE gels, and then transferred to polyvinylidene
diﬂuoride (PVDF) membranes. After blocking the residual protein sites
on the PVDF membrane with ImmunoBlock (Dainippon-Pharm.,
Osaka, Japan), the membrane was incubated with anti-ETA (39 and
54 kDa; 1: 1000), anti-ETB (50 kDa; 1:1000), anti-eNOS (140 kDa;
1:1000), anti-Mn-SOD (25 kDa; 1:1000), anti-Cu/Zn-SOD (20 kDa;
1:1000), anti-EC-SOD (45 kDa; 1:1000), or anti-gp91phox (58 kDa;
1:1000) in blocking solution. HRP-conjugated, anti-mouse or anti-
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by detection using SuperSignal (ThermoScientiﬁc, Rockford, IL, USA).
To normalize the data, we used β-actin as a housekeeping protein. The
β-actin protein levels were determined after stripping the membrane
and probing with β-actin monoclonal primary antibody (42 kDa; 1:
5000), with HRP-conjugated anti-mouse IgG as the secondary antibody.
The resulting bands were analyzed using CS Analyzer 3.0 software
(ATTO, Tokyo, Japan).
Statistical analysis
Data are expressed as means ± SEM. Concentration–response
curves with agonists were ﬁtted using a nonlinear interactive ﬁtting
program (Graph Pad Prism 5.0; GraphPad Software Inc., San Diego, CA,
USA). Statistical evaluations were performed using one-way analysis
of variance (ANOVA) followed by Bonferroni's test for multiple compar-
isons. Statistical evaluations of concentration–response curves were
performed using two-way ANOVA with repeated measures followed
by a Bonferroni post-hoc test. Values of P b 0.05 were considered
signiﬁcant.
Results
Various parameters
As shown in Table 1, the non-fasted blood glucose levels were signif-
icantly higher in the OLETF than LETO groups. The body weight and
plasma insulin levels were similar between OLETF and LETO groups.
The systolic blood pressure, plasma cholesterol, triglyceride, HDL, and
NEFA levels were all signiﬁcantly higher in the OLETF than LETO groups.
In LETO rats, the signiﬁcant effects of treatment with EGCGwere lower-
ing of systolic blood pressure and bodyweight (vs. untreated LETO rats).
In OLETF rats, treatment with EGCG signiﬁcantly lowered plasma
triglycerides (vs. untreated OLETF rats).
Effects of EGCG on ET-1- and PE-induced contractions in carotid artery
The cumulative administration of ET-1 (10−10 to 10−7 M) (Fig. 1)
led to a concentration-dependent contraction of carotid arterial rings
from EGCG-untreated and -treated OLETF and LETO rats. The maximal
response of ET-1 at 10−7 M was signiﬁcantly increased in OLETF rats
compared to LETO rats in the presence (Fig. 1A) and absence (Fig. 1B)
of endothelium. In OLETF rats, long-term treatment with EGCG sup-
pressed the ET-1-induced contraction of the endothelium-intact prepa-
ration (Fig. 1A), and tended to reduce the value of pD2 [7.95 ± 0.07
(n = 10) (EGCG-treated OLETF group) vs. 8.15 ± 0.06 (n = 10)
(EGCG-untreated OLETF group)]. The difference in ET-1-induced
contraction between EGCG-treated and -untreated OLETF rats disap-
peared in the endothelium-denuded preparation (Fig. 1B), and the
pD2 values in endothelium-denuded rings from OLETF rats were similar
between the two groups [8.18 ± 0.05 (n = 10) (EGCG-treated OLETF
group) vs. 8.29 ± 0.05 (n = 10) (EGCG-untreated OLETF group)].Table 1
Various parameters in four experimental groups.
Parameters LETO LETO/EGCG
BW (g) 550.3 ± 7.2 (17) 489.0 ± 5.8
SBP (mmHg) 126 ± 2 (17) 108 ± 3 (1
Glucose (mg/dl) 118.9 ± 1.8(17) 119.1 ± 3.9
Insulin (ng/ml) 2.52 ± 0.2 (16) 1.87 ± 0.1
Cholesterol (mg/dl) 102.2 ± 4.1 (17) 87.0 ± 2.6
Triglyceride (mg/dl) 98.2 ± 9.1 (17) 81.3 ± 7.2
HDL (mg/dl) 65.4 ± 2.4 (17) 70.7 ± 2.2(
NEFA (mEq/l) 0.48 ± 0.03 (17) 0.42 ± 0.02
BW, bodyweight; SBP, systolic blood pressure; HDL, high-density lipoprotein; NEFA, nonesteriﬁ
fatty; EGCG, epigallocatechin gallate. Values are means ± SEM. Number of determinations witIn the LETO rats, EGCGdidnot affect ET-1-induced contraction in the pres-
ence [pD2, EGCG-treated LETO: 8.18 ± 0.09 (n = 10) vs. -untreated
LETO: 8.21 ± 0.05 (n = 10)] or absence [pD2, EGCG-treated LETO:
8.28 ± 0.06 (n = 10) vs. -untreated LETO: 8.41 ± 0.06 (n = 10)] of
endothelium.
As shown in Fig. 1, PE-induced contractions in the presence (Fig. 1C)
or absence (Fig. 1D) of endothelium were increased in carotid arteries
from OLETF rats compared to those from LETO rats, and these PE-
induced responses were not affected by EGCG treatment in either the
OLETF or LETO group.
Effects of EGCG on ACh- and SNP-induced relaxations in carotid artery
To evaluate the role of the endothelial function as a determinant
of the beneﬁcial effect of EGCG on the ET-1-induced contraction, we
investigated endothelium-dependent and -independent relaxations in
carotid arteries (Fig. 2). As shown in Fig. 2A, the ACh-induced relaxation
was signiﬁcantly reduced in carotid arteries from OLETF rats compared
to those from LETO rats. In OLETF arteries (Fig. 2A), ACh-induced relax-
ation was signiﬁcantly increased in EGCG-treated groups compared to
EGCG-untreated groups, and the pD2 value tended to increase in
EGCG-treated compared to EGCG-untreated groups [EGCG-treated:
6.89 ± 0.28 (n = 7) vs. -untreated: 6.01 ± 0.25 (n = 7)]. On the
other hand, treatment with EGCG did not affect the ACh-induced relax-
ations in carotid arteries from LETO rats (Fig. 2A). As shown in Fig. 2B,
the SNP-induced relaxationwas signiﬁcantly reduced in carotid arteries
from OLETF rats compared to those from LETO rats. EGCG did not affect
the SNP-induced relaxations in either theOLETF or LETO (Fig. 2B) group.
Effects of EGCG on protein expressions in carotid artery
To investigate the molecular mechanisms underlying the beneﬁcial
effects of EGCG on the ET-1-induced contraction in OLETF rats, we
examined whether the expressions of ET receptors and eNOS proteins
in carotid arteries were altered by EGCG treatment (Fig. 3). The ETA
receptor density was analyzed by combining data for two bands
(at 54/39 kDa; corresponding to the native/glycosylated forms of the
receptor), as reported previously (Ergul et al., 2003; Kobayashi et al.,
2008). EGCG did not alter the expressions of ETA (Fig. 3A), ETB
(Fig. 3B), or eNOS (Fig. 3C) in either OLETF or LETO rats.
Oxidative stress, deﬁned as an increase in the steady-state levels of
reactive oxygen species, may occur as a result of increased free radical
production, which is largely attributable to NAD(P)H oxidase activation
in the vascular system (Cai et al., 2003), and/or to a reduction in anti-
oxidant defence systems including SODs (Kamata and Kobayashi,
1996). Several reports suggested that SOD could normalize the endo-
thelial function and altered ET-1-induced contraction under some con-
ditions (Kamata and Kobayashi, 1996; Martínez-Revelles et al., 2012).
Thus, we subsequently investigated whether the expressions of SOD
proteins in carotid arteries were altered by EGCG treatment (Fig. 3).
EGCG did not alter the expressions of Mn-SOD (Fig. 3D), Cu/Zn-SOD
(Fig. 3E), or EC-SOD (Fig. 3F) in either OLETF or LETO rats. Moreover,OLETF OLETF/EGCG
(17)* 553.6 ± 16.1 (17) 538.8 ± 13.9 (17)
7)* 154 ± 2 (17)* 146 ± 4(17)*
(17) 471.6 ± 22.7(17)* 439.1 ± 28.1(17)*
(17) 1.79 ± 0.4 (16) 1.32 ± 0.1 (17)
(17) 129.0 ± 7.0 (17)* 130.0 ± 5.1 (17)*
(17) 495.9 ± 59.3 (17)* 340.1 ± 30.2 (17)*,#
17) 97.6 ± 6.0(17)* 96.9 ± 4.2(17)*
(17) 0.82 ± 0.07 (17)* 0.67 ± 0.04 (17)*
ed fatty acid; LETO, Long–Evans TokushimaOtsuka; OLETF, Otsuka Long–Evans Tokushima
hin parentheses. *P b 0.05 vs. LETO. #P b 0.05 vs. OLETF.
Fig. 1. Concentration–response curves for ET-1 (A, B) and PE (C, D) in endothelium-intact (A, C) and endothelium-denuded (C, D) carotid arterial rings isolated from EGCG-
treated and -untreated OLETF and LETO rats. Ordinates show the increase in tension (mN) measured at the peak response. Data are means ± SEM; n = 10. *P b 0.05, LETO
vs. OLETF #P b 0.05, OLETF/EGCG vs. OLETF group as determined by two-way repeated-measures ANOVA.
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NAD(P)H oxidase (Cai et al., 2003), were not altered in carotid arteries
from these four groups (Fig. 3G).Fig. 2. Concentration–response curves for acetylcholine (ACh) (A)- and sodiumnitroprusside
(SNP) (B)-induced relaxation of carotid arterial rings fromEGCG-treated or -untreatedOLETF
and LETO rats. Each relaxation response is expressed as a percentage of the contraction
induced by PE. Data are means ± SEM; n = 7. *P b 0.05, LETO vs. OLETF #P b 0.05, OLETF/
EGCG vs. OLETF group as determined by two-way repeated-measures ANOVA.Discussion
The main conclusion to be drawn from the present study is that, in
OLETF rats, a T2DM model, long-term treatment with EGCG attenuates
the ET-1-induced contraction and increases endothelium-dependent
relaxation, even when such treatment starts at the chronic stage of the
disease.
Although there are many therapeutic approaches for T2DM and its
associated vascular complications at present, conventional therapies
that are both effective and safe are still insufﬁcient. Therefore, develop-
ing alternative approaches to treatment as well as prevention is
imperative (Munir et al., 2013). For this, functional foods may be a
therapeutic alternative. A number of large, well-performed epidemio-
logic investigations demonstrated that the consumption of functional
foods containing bioactive polyphenols including green tea is associated
with improvements of metabolic and/or cardiovascular morbidity and
mortality (Kuriyama et al., 2006; Wolfram, 2007; Babu and Liu, 2008;
Munir et al., 2013). Indeed, a number of reports suggested that EGCG
had preventive effects against metabolic and vascular dysfunction in di-
abetes (Wolfram, 2007; Babu and Liu, 2008;Munir et al., 2013). Howev-
er, few studies have focused on whether EGCG has therapeutic (not
preventive) effects on the vascular function in diabetes at the chronic
stage of the disease.
OLETF rats manifest stable clinical and pathological features that re-
semble human T2DM (Kawano et al., 1992). This model shows not only
high glucose but also abnormal lipid proﬁles. In the present study, when
long-term EGCG administrationwas started at a chronic stage, it did not
affect blood glucose. However, it could lower triglyceride levels. Some
reports have suggested a relationship between triglycerides and the
vascular function including the ET-1 system (Perassolo et al., 2008;
Sokup et al., 2012). Therefore, the beneﬁcial effects of EGCG on ET-1-
induced contraction may be partly due to reduced triglyceride levels.
Based on our present and previous studies (Matsumoto et al., 2009a,)
and those of others (Wu and Bohr, 1990; Tirapelli et al., 2005), the
Fig. 3.Analysis of ETA, ETB, eNOS, SODs, and gp91phox protein expressions in carotid arteries isolated from four groups.Upper: representativeWestern blots. Lower: corresponding densitometric
analysis showing the expressions of ETA (39 and 54 kDa) (A), ETB (50 kDa) (B), eNOS (140 kDa) (C), Mn-SOD (25 kDa) (D), Cu/Zn-SOD (20 kDa) (E), EC-SOD (45 kDa) (F), and gp91phox
(58 kDa) in carotid arteries fromEGCG-treated or -untreatedOLETF and LETO rats. The ETA receptor densitywas determined by combining data for two bands (at 39 and54 kDa; corresponding
to the native and glycosylated forms of the receptor, respectively). Densitometric data are expressed as means ± SEM; n = 7 or 8.
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contraction. In the present study, we found that: 1) the ET-1-induced
contraction was attenuated by EGCG treatment in carotid arteries from
OLETF rats but not from LETO rats, 2) the difference in ET-1-induced con-
traction between EGCG-treated and -untreated OLETF rats was abolished
by endothelium denudation, 3) the PE-induced contraction was not
affected by EGCG treatment in both OLETF and LETO groups, 4) ACh-
induced endothelium-dependent relaxation was increased by EGCG
treatment in OLETF rats but not in LETO rats, and 5) SNP-induced
endothelium-independent relaxation was not affected by EGCG treat-
ment in both OLETF and LETO groups. Based on our present data, EGCG
speciﬁcally affects the ET-1-mediated but not α1-adrenergic receptor-
mediated contraction in the OLETF carotid artery, and the endothelial
function contributes to the suppressive effects of EGCG on ET-1-induced
contraction in carotid arteries from OLETF rats. ET-1 is widely recognized
to activate ETA receptors on VSMCs to induce contraction and ETB
receptors on ECs to induce relaxation (Ergul, 2011; Ohkita et al., 2012;
Pernow et al., 2012). When considering endothelium-derived relaxing
factors (EDRFs) as counteracting ET-1-mediated contraction, the contri-
bution of ETB-mediated EDRF signaling may be important in the OLETF
carotid artery since EGCG affected neither PE-induced contraction nor
SNP-induced relaxation in OLETF carotid artery. Indeed, some reports
have suggested that ET-1-induced contraction is regulated by the balance
of ET-receptor signaling in both ECs andVSMCs (Matsumoto et al., 2009a;
Ergul, 2011). In the present study, EGCG did not affect the expressions of
both ETA and ETB receptors in carotid arterial homogenate including ECs
and VSMCs. We could not rule out the contribution of ETB-mediated re-
laxant effects on ET-1-induced contraction, and so further study is
required.
Improvement of the endothelial function in diabetes is a very impor-
tant issue. One of the factors adversely affecting the endothelial functionis oxidative stress (Rask-Madsen and King, 2007; Potenza et al., 2009).
In some reports on diabetic arteries, the bioavailability of NO was
reduced by increased oxidative stress (Matsumoto et al., 2008;
Potenza et al., 2009). Since NO can counteract the effects of ET-1
(Matsumoto et al., 2008; Pernow et al., 2012), the suppression of
oxidative stress would be effective against diabetic vascular dysfunc-
tion. Several studies reported increased expression and activity of
NAD(P)H oxidase, one of the major sources of superoxide in vessels, in
arteries fromOLETF rats involving different vessels and stages of disease
(Kim et al., 2003; Matsui et al., 2011), and green tea extract (Ihm et al.,
2012) or catechin (Ihm et al., 2009) suppressed oxidative stress in the
OLETF arteries. In the present study, on treatment with EGCG within
the timescale studied here, the EGCG did not affect the protein expres-
sion of eNOS, SODs, or gp91phox. This discrepancy may be related to
the vessel types, stage of the disease, or the EGCG treatment regimen.
We could not rule out the role of oxidative stress in EGCG-treated
OLETF vessels, and so further research is required.
Several animal models have been employed to gain further insight
into the alterations in the ET system associated with diabetes and
hypertension (Ergul, 2011; Ohkita et al., 2012; Pernow et al., 2012). In
the OLETF rats, EGCG could partially improve endothelial dysfunction
and attenuate ET-1 induced contraction in the carotid artery. However,
there were no accompanying changes in the blood pressure in the
EGCG-treated OLETF rats. There are several reports on the relationship
between EGCG and blood pressure (Potenza et al., 2007; Wang et al.,
2012). For example, Potenza et al. (2007) found that 3-week EGCG
treatment of SHR, a model of metabolic syndrome with hypertension,
insulin resistance, and overweightness, starting at 9 weeks old, could
normalize insulin-induced vasodilation in mesenteric vascular beds
and lower the blood pressure. In the present study, we aimed to
investigate the putative therapeutic rather than preventive effect of
205T. Matsumoto et al. / Life Sciences 118 (2014) 200–205EGCG on the ET-1-induced response and endothelial function, and to this
end, we administered EGCG chronically (for 2 months) to establish
diabetic OLETF rats (which also exhibited hypertension). Within the
timescale studied here, EGCG did not inﬂuence the blood pressure,
even if it partially restored the ET-1 and endothelial function. If OLETF
rats are treated with EGCG for a longer time, or if treatment is started
at an earlier stage of the disease, EGCG may potentially affect the blood
pressure. To establish if it has such a beneﬁcial effect, future research
will be required to focus, for instance, on time-course alterations in the
blood pressure and endothelial functions of animals in a diabetic state.
Conclusion
In conclusion, our ﬁndings suggest that chronic treatment with EGCG
normalizes endothelial dysfunction and attenuates the ET-1-induced
contraction involved in diabetic vasculopathy. Our ﬁndings may aid in
understanding the metabolic and vascular health beneﬁts of green tea
consumption for diabetic patients.
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